vascuCAP vs ElucidVivo A.3

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

Both vascuCAP (now ElucidVivo/PlaqueIQ) and ElucidVivo A.3 are FDA-cleared AI solutions from Elucid Bioimaging, offering quantitative analysis of arterial plaque composition from CT angiography to aid in cardiovascular risk assessment and treatment decisions. ElucidVivo A.3 appears to be a refined iteration, building upon the core capabilities of vascuCAP with potentially enhanced visualization features and the addition of fractional flow reserve (FFRct) derivation. Therefore, they are direct competitors, with ElucidVivo A.3 likely representing the current offering or an advanced version of the technology.

When choosing between vascuCAP (now ElucidVivo/PlaqueIQ) and ElucidVivo A.3, physicians should consider their specific needs for cardiovascular risk assessment and treatment optimization. Both tools, developed by Elucid Bioimaging, are FDA-cleared AI software designed for non-invasive CT angiography analysis, quantifying plaque composition, and aiding in treatment decisions. They share core functionalities such as AI-enabled CT angiogram analysis, 3D visualization of arterial vessels and plaque, and the quantification of various plaque components like lipid-rich necrotic core and calcification. Both also integrate with DICOM and offer PACS/EMR interoperability, with deployment options including cloud and on-premise.

The key practical difference lies in their stated feature sets. While vascuCAP emphasizes risk stratification for stroke and heart attack and support for personalized treatment decisions, ElucidVivo A.3 explicitly highlights its ability to derive fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. This suggests that ElucidVivo A.3 may offer a more in-depth physiological assessment of coronary lesions beyond just plaque morphology. Therefore, a physician primarily focused on comprehensive risk stratification and general plaque characterization for broad treatment decisions might lean towards vascuCAP. In contrast, a physician seeking more advanced physiological insights, particularly FFRct derivation for a deeper understanding of lesion hemodynamics, would find ElucidVivo A.3 to be the more suitable choice.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Frequently Asked Questions

What is the relationship between vascuCAP and ElucidVivo A.3, given they are both from Elucid Bioimaging?

Tool A, vascuCAP, is described as 'now ElucidVivo/PlaqueIQ,' indicating a rebranding or evolution of the product line. Tool B, ElucidVivo A.3, appears to be a specific version under the ElucidVivo branding, suggesting it is a newer iteration or a distinct offering within the same product family.

What specific plaque components can each tool quantify from CT angiography images?

vascuCAP quantifies lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images.

Does either tool offer advanced physiological assessment capabilities beyond plaque quantification, such as Fractional Flow Reserve (FFRct)?

ElucidVivo A.3 explicitly states that it derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. vascuCAP's listed features do not explicitly mention FFRct derivation.

What are the key visualization features offered by each tool for arterial vessels and plaque?

Both tools offer 3D visualization of arterial vessels and plaque. ElucidVivo A.3 additionally provides rotatable curved MPR vessel views and cross-sections.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform